Castle Biosciences (CSTL) Non-Current Deferred Tax Liability (2021 - 2026)

Castle Biosciences (CSTL) has 6 years of Non-Current Deferred Tax Liability data on file, last reported at $2.3 million in Q1 2026.

• Quarterly Non-Current Deferred Tax Liability rose 177.78% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (up 177.78% YoY) and the FY2025 annual result came in at $2.3 million, down 90.39% from the prior year.
• Non-Current Deferred Tax Liability held at $2.3 million in Q1 2026 per CSTL's latest filing, from $2.3 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $27.1 million in Q4 2022, with the low at $206000.0 in Q1 2024.
• Average Non-Current Deferred Tax Liability over 5 years is $6.0 million, with a median of $1.6 million recorded in 2025.
• Year-over-year, Non-Current Deferred Tax Liability surged 856.92% in 2024 and slumped 90.39% in 2025.
• Castle Biosciences' Non-Current Deferred Tax Liability stood at $27.1 million in 2022, then decreased by 9.0% to $24.7 million in 2023, then retreated by 1.58% to $24.3 million in 2024, then tumbled by 90.39% to $2.3 million in 2025, then retreated by 0.43% to $2.3 million in 2026.
• Business Quant data shows CSTL's Non-Current Deferred Tax Liability at $2.3 million in Q1 2026, $2.3 million in Q4 2025, and $3.2 million in Q3 2025.